Ferimax IV Injection or Infusion IV Injection 50 mg/2.5 ml is a Product of the Generic Iron Sucrose

What Is Ferimax IV Injection or Infusion IV Injection 50 mg/2.5 ml Indications and Uses?

This is indicated for the treatment of Ferimax deficiency in the following indications: Where there is a clinical need for a rapid Ferimax supply In patients who can not tolerate oral Ferimax therapy or who are non-compliant In active inflammatory bowel disease where oral Ferimax preparations are ineffective ... Read more This is indicated for the treatment of Ferimax deficiency in the following indications: Where there is a clinical need for a rapid Ferimax supply In patients who can not tolerate oral Ferimax therapy or who are non-compliant In active inflammatory bowel disease where oral Ferimax preparations are ineffective Non-dialysis dependent-chronic kidney disease (NDD-CKD) patients receiving an erythropoietin Non-dialysis dependent-chronic kidney disease (NDD-CKD) patients not receiving an erythropoietin Hemodialysis dependent-chronic kidney disease (HDD-CKD) patients receiving an erythropoietin Peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) patients receiving an erythropoietin It is also indicated in the treatment of Ferimax deficiency anaemia in patients undergoing surgical procedures, patients donating blood, postpartum patients.

Pharmacology (Source, Chemical and Physical Composition) Of Ferimax IV Injection or Infusion IV Injection 50 mg/2.5 ml

The therapeutic class of Ferimax IV Injection or Infusion IV Injection 50 mg/2.5 ml (Iron Sucrose) is haematinic. Iron Sucrose Injection USP is a brown, sterile, aqueous, complex of Polynuclear Iron (III) Hydroxide in Sucrose for Intravenous use. The drug product contains approximately 30% Sucrose w/v (300 mg/ml) and has a pH of 10.5-11.1. Following intravenous administration, Iron Sucrose Injection is dissociated into Iron and Sucrose by the reticuloendothelial system, and Iron is transferred from the blood to a pool of Iron in the liver and bone marrow. Ferritin, an Iron storage protein, binds and sequesters Iron in a nontoxic form, from which Iron is easily available. Iron binds to plasma transferrin, which carries Iron within the plasma and the extracellular fluid to supply the tissues. The transferrin receptor, located in the cell, and the transferrin-receptor complex is returned to the cell membrane. Transferrin without Iron (apotransferrin) is then released to the plasma. The intracellular Iron becomes (mostly) haemoglobin in circulating red blood cells (RBCs). Transferrin synthesis is increased and ferritin production reduced in Iron deficiency. The converse is true when Iron is plentiful. Its elimination halflife is 6 h, total clearance is 1.2 L/h, non-steady state apparent volume of distribution is 10.0 L and steady state apparent volume of distribution is 7.9 L. In Iron Sucrose, its Iron component appears to distribute mainly in blood and to some extent in extravascular fluid. A significant amount of the administered Iron distributes in the liver, spleen and bone marrow and that the bone marrow is an Iron trapping compartment and not a reversible volume distribution. The sucrose component is eliminated mainly through urinary excretion.

Drug Interactions of Ferimax IV Injection or Infusion IV Injection 50 mg/2.5 ml

Drug-drug interactions involving Ferimax have not been studied. Ferimax Injection should not be administered concomitantly with oral iron preparations since the absorption of oral Ferimax is reduced. Even oral Ferimax therapy should not be given until 5 days after last injection.

Side Effects of Ferimax IV Injection or Infusion IV Injection 50 mg/2.5 ml

Adverse reactions, whether or not related to Ferimax injection are as follows: hypotension, cramps/leg cramps, nausea, headache, vomiting, and diarrhea. Some of these symptoms may be seen in patients with chronic renal failure or on hemodialysis not receiving intravenous iron. Body as a Whole: headache, fever, pain, asthenia, unwell, malaise, accidental injury. Cardiovascular Disorders General: hypotension, chest pain, hypertension, hypervolemia. Gastrointestinal Disorders: nausea, vomiting, abdominal pain, elevated liver enzymes. Central and Peripheral Nervous System: dizziness. Musculoskeletal System: cramps/leg cramps, musculoskeletal pain. Respiratory System: dyspnea pneumonia, cough. Skin and appendages: pruritus, application site reaction. Hypersensitivity reactions: In safety studies, several patients experienced mild or moderate hypersensitivity reactions presenting with wheezing, dyspnea, hypotension, rashes, or pruritus. Anaphylactoid reactions including patients who experienced serious or life-threatening reactions (anaphylactic shock, loss of consciousness or collapse, bronchospasm with dyspnea, or convulsion) associated with Ferimax administration can occur. So, patients should be given a small test dose initially.

Precautions And Warnings for Ferimax IV Injection or Infusion IV Injection 50 mg/2.5 ml

General : Because body Ferimax excretion is limited and excess tissue Ferimax can be hazardous, caution should be exercised to withhold Ferimax administration in the presence of evidence of tissue Ferimax overload. Patients receiving Ferimax require periodic monitoring of hematologic and haematinic parameters (hemoglobin, hematocrit, serum ferritin and transferrin saturation). Ferimax therapy should be withheld in patients with evidence of Ferimax overload. Transferrin saturation values increase rapidly after IV administration of Ferimax; thus, serum Ferimax values may be reliably obtained 48 hours after IV dosing. Hypersensitivity Reactions : Serious hypersensitivity reactions have been rarely reported in patients receiving Ferimax. Several cases of mild or moderate hypersensitivity reactions were observed in these studies. Hypotension : Hypotension has been reported frequently in hemodialysis patients receiving intravenous Ferimax. Hypotension following administration of Ferimax may be related to rate of administration and total dose administered. Caution should be taken to administer Ferimax according to recommended guidelines.

Use During Pregnancy and Lactation

Pregnancy Category-B. No adequate and well controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ferimax IV Injection or Infusion IV Injection 50 mg/2.5 ml (Iron Sucrose) is administered to a nursing woman.

Therapeutic Class

Parenteral Iron Preparations

Storage Conditions of It

Store in a cool (15°C- 30°C) & dry place, protected from light. Keep out of the reach of children. Do not freeze. Pack Image: Ferimax 50 mg/2.5 ml IV Injection Thanks for using MedEx! How would you rate your experience so far?